Tobias Feuchtinger
Principal Investigator
Department of Paediatrics
Medical Center University of Freiburg
Breisacherstrasse 62
79106 Freiburg
- +49 761/270-45060
- tobias.feuchtinger@uniklinik-freiburg.de
- Homepage
Current position
Director (Abteilungsleiter) W3 Professor Department of Pediatric Hematology and Oncology, Medical Center Freiburg
Academic training
| 1993–1999 | Medical studies, Universities of Hamburg, Witten-Herdecke and Case Western Reserve University Cleveland/Ohio (US) |
Advanced academic qualifications
| 2009 | Prof. R. Handgretinger, Habilitation: “Adenovirus infection post SCT and adoptive T-cell therapy”, Tübingen University |
| 2000 | Prof. U. Schauer, Doctoral thesis: “Isolation of CD4+ dendritic cells and infect associated stimulation”, University Hospital Bochum, Laboratory of Immunology |
Postgraduate positions
| Since 2023 | Full Professor and Medical Director, Department of Pediatric Hematology and Oncology, Medical Center Freiburg – University of Freiburg |
| 2015–2023 | W2 Professor of Pediatric Hematology/ Oncology and head of Department of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, LMU Munich |
| 2009–2015 | Attending physician Department of Pediatric Hematology/Oncology, Tübingen University |
| 2003–2015 | Group leader & Qualified Person (GMP) Laboratory Immunotherapy, Tübingen University |
| 2000–2009 | Internship and Residency at University Children's Hospital Tübingen |
Publications listed in PubMed®
Publications (based on CRC1479 funding)
Maas-Bauer K, Meyer T, Yücel M, Garofalaki M, Koßmann S, Biavasco F, Lysandrou M, Waterhouse M, Feuchtinger T, Pfeifer D, Ingelfinger F, Wertheimer T, Duyster J, Ahn JS, Soiffer RJ, Finke J, Wäsch R, Spyridonidis A, Kim DDH, Wehr C, Zeiser R. Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2026 Apr 3. doi: . Epub ahead of print.
Fetsch V, Schwöbel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Köhler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Färber J, Braun LM, Zähringer A, Lübbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kühn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R. Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. Blood. 2026 Jan 29;147(5):584-601. doi: 10.1182/blood.2025029712.
Highlighted by: Chakraverty R. Menin inhibitors: a 2-in-1 defense versus AML immune evasion. Blood (2026) 147 (5): 482–483.
Contact
